Humacyte, Inc. (NASDAQ:HUMA – Get Rating) CEO Laura E. Niklason sold 2,625,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $2.75, for a total value of $7,218,750.00. Following the completion of the transaction, the chief executive officer now owns 15,365,736 shares in the company, valued at approximately $42,255,774. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Humacyte Stock Performance
NASDAQ HUMA traded up $0.09 on Friday, hitting $3.70. 376,419 shares of the company’s stock were exchanged, compared to its average volume of 252,662. The company has a debt-to-equity ratio of 0.42, a current ratio of 5.67 and a quick ratio of 5.67. The firm’s 50-day moving average price is $3.55 and its two-hundred day moving average price is $3.07. Humacyte, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $6.38. The firm has a market cap of $382.32 million, a price-to-earnings ratio of -12.33 and a beta of 1.22.
Analyst Upgrades and Downgrades
Separately, Benchmark reiterated a “buy” rating and set a $16.00 target price on shares of Humacyte in a research report on Monday, March 27th.
Hedge Funds Weigh In On Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).
- Get a free copy of the StockNews.com research report on Humacyte (HUMA)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.